Abstract for the 2017 Focused Update to the 2016 Expert Consensus Decision Pathway. In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. GBJ, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R, 2016 Canadian Cardiovascular Society Guidelines for the management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, Canadian Journal of Cardiology (2016), doi: 10.1016/ j.cjca.2016.07.510. DHMH/PHPA/MCHB/OFPHV MARYLAND TITLE X FAMILY PLANNING PROGRAM CLINICAL GUIDELINES Dyslipidemia - Revised January 2017 Page 1 of 4 DYSLIPIDEMIA I. INTRODUCTION Coronary heart disease (CHD) is the single leading cause of death of women in the United States. Dyslipidemia is a major risk factor for CHD in women. For women at AHA Community page for Dyslipidemia and Treatments. Skip to main content. Hello, Guest! Become A Member Sign In Find My Account Sidney C. Smith, Jr., MD interviews Lynne Braun, PhD, CNP about what the 2018 Guideline for the Management of Blood Cholesterol recommends as optimal treatment for Hyperlipidemia refers to increased levels of lipids (fats) in the blood, including cholesterol and triglycerides. Secondary causes of dyslipidemia; Statins: Actions, side effects, and administration; Many expert groups have guidelines for cholesterol screening. The guidelines differ in The American college of cardiology (ACC) and American Heart Association (AHA) in combination with National Heart, Lung and blood institute (NHLBI) have released 4 new guidelines. At the invitation of the National Heart, Lung, and Blood Institute (NHLBI), The Title: Dyslipidemia Guidelines Tool_eng_2017_fnl Created Date: 3/30/2017 10:07:15 AM Clinical Guidelines: ADA 2017 Standards of Medical Care in Diabetes. Publish date